News for GTH Stock

Genetron Health Announces Completion of Going Private Transaction Genetron Health Announces Shareholders’ Approval of Merger Agreement Genetron Health to Hold Extraordinary General Meeting of Shareholders Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction Genetron Health Announces Receipt of Notification from Nasdaq Global Smart (AI) In-Vitro Diagnostics (IVD) Market Research Report 2023: Instrumentation, Automation and Diagnostic Trends - Decentralization and Point Of Care Global In Vitro Diagnostics Market Outlook Report 2023-2028: Opportunities Abound in Increasing Product Launches, Mergers & Acquisitions, and Advances in Molecular Diagnostics Global Genomic Cancer Panel and Profiling Markets, 2023-2027: An Exploding Market as Physicians Use All the Information they Can Get in the Battle Against Cancer World Molecular Diagnostics for Cancer Markets Report 2023: The New Automation, Decentralization and Point Of Care Global Liquid Biopsy Market Analysis Report 2023-2027: The Market has Moved Out of the Development Phase and Into the Growth Phase World Whole Genome and Exome Sequencing Market Report 2023-2027: Pathogen Challenges, Diagnostic Factors, Interpreting the Code, Fertility Technology Driving Growth Global Companion Diagnostic Markets Report 2023: Companion Diagnostics are Changing Cancer Management and are Poised to Move into New Therapeutic Eras Global Genetic Testing Market Report 2023-2027: New Knowledge, Combined with Lower Pricing is Driving the Genetic Testing Industry to Record Growth Market Forecasts for Immuno-Oncology Diagnostics 2023: Sector Represents a Revolution in Cancer Therapy COVID-19 Pandemic Emphasized the Importance of In Vitro Diagnostics, More than $127 Billion Worth Market Opportunity in the IVD Market - Arizton Global Immuno-Oncology Diagnostics Market Report 2023-2028: Diagnostic Companies and Instrumentation Suppliers are Jockeying for Position in a New Approach to Conquering Cancer Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement Genetron Health Announces Receipt of Notification from Nasdaq Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 46% p.a., Reaching $8.6B by 2027 – Market Report by DeciBio Consulting LLC Genetron Health Reports Unaudited Second Quarter 2022 Financial Results Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day Genetron Health Receives CAP Accreditation for its Maryland Laboratory Genetron Health Reports Unaudited First Quarter 2022 Financial Results Genetron Health Releases 10 New Research Results at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Genetron Health Receives CE Mark for FusionScan Plus Kit for Human Multi-Genes Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022 Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD® Genetron Health Presents 17 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2022 Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™’s potential in MRD Assay Developments Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results Genetron Health to Participate in the Credit Suisse Asian Investment Conference Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022 Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC Genetron Health to Participate in Upcoming Investor Conferences Genetron Health Reiterates Full Year 2021 Revenue Guidance Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible Genetron Health Reports Third Quarter 2021 Unaudited Financial Results Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China Genetron Health Reveals Two Cancer Research Study Results at the Association for Molecular Pathology 2021 Annual Meeting Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit Genetron Health Announces Publication of Enhanced Variant Caller Performance Data in Briefings in Bioinformatics Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development Genetron Health to Announce Third Quarter 2021 Financial Results and Host Investor Call on November 30, 2021 Genetron Health’s Multi-Gene Mutation Detection Kit Onco PanScan™ Obtains CE Mark Genetron Health Wins Second Prize of China’s National Science and Technology Progress Award for Contributions to Lung Cancer Precision Medicine Project Genetron Health’s Liver Cancer Screening Results and Technology Findings Included in the Chinese Journal of Hepatology Genetron Health and Fosun Pharma Announce Exclusive Partnership to Commercialize Seq-MRD® in China Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021 Genetron Added to FTSE Russell Global Equity Index Series Genetron Health’s Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021 Genetron Health Reports Second Quarter 2021 Unaudited Financial Results Genetron Health to Host Calls Following Earnings and Participate in an Upcoming Investor Conference Genetron Health Reaches Strategic Partnership with Yikon Genomics, Expanding S5 Platform’s Reach to Reproductive Health Field Genetron Health to Announce Second Quarter 2021 Financial Results and Host Investor Call on August 24, 2021 Genetron Health Tops NCCL’s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks Genetron Health Partners with Guizhou Province’s Dafang County to Lead Liver Cancer Early Screening Project AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test Genetron Health Enters into Platform Partnership with World Economic Forum Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Genetron Health Reports First Quarter 2021 Unaudited Financial Results Genetron Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer Genetron Health to Announce First Quarter 2021 Financial Results and Host Investor Call on May 24, 2021 Genetron Health to Present at Upcoming Investor Conferences Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021 Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021 Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31 Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021 Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021 Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China COVID-19 Highlights Role of Early Detection in Fighting Threatening Diseases, Especially Cancer, Genetron CEO Tells CNBC Conference Genetron Health Named One of the “50 Smartest Companies in China 2020” by MIT Technology Review Genetron Health to Present at CNBC East Tech West Conference Genetron Health Reports Third Quarter 2020 Unaudited Financial Results and Provides Business Update Genetron Health to Present at Six Upcoming Investor and Industry Conferences Genetron Health to Announce Third Quarter Unaudited Financial Results and Host Investor Call on November 9, 2020 Genetron Health Enters Exclusive Global Licensing Agreement with ImmuQuad Biotechnologies to Develop and Commercialize Minimal Residual Disease Assays in Hematologic Cancer Genetron Health Receives U.S. FDA Breakthrough Device Designation for its Blood-based NGS Test for Early Detection of Hepatocellular Carcinoma Genetron Health and CStone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in Development for Avapritinib Genetron Health to Highlight Data from 18 Studies at ESMO 2020 Genetron Health and dMed Announce Partnership Agreement Genetron Health to Present at Upcoming Investor Conferences Genetron Health Joins Major R&D Project Led by the Ministry of Science and Technology in China for Early Screening of Lung and Digestive System Cancers Genetron Health Reports Second Quarter 2020 Unaudited Financial Results Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020 Genetron Health Announces Pricing of Initial Public Offering Genetron Health to Present at Canaccord Genuity 40th Annual Growth Conference Genetron Health Presents Cancer Clinical Research Data at AACR Virtual Annual Meeting Highlighting the Sensitivity and Specificity of its NGS Technology in Precision Oncology